Research Interest：
Biographical Sketch:
He has more than 20 years of innovative vaccines R&D experience, including preclinical research, clinical research, and product registration. Zhu Tao obtained his Ph.D. in Chemical Engineering from the University of Pittsburgh in 2003. He established five leading technology platforms, including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant VLP technology, mRNA vaccine technology as well as formulation and delivery technology. He also led the research and development of more than 10 innovative vaccine products, including the world's first inhalation COVID-19 vaccine Convidecia Air, the WHO recommended adenovirus vector COVID-19 vaccine Convidecia, the only available recombinant Ebola vaccine, and the China’s first tetravalent meningococcal conjugate vaccine. He has obtained 29 patent authorizations, and has published 61 scientific research papers in well-known domestic and foreign journals such as the Lancet.
Honors and Awards
• In November 2020, he received recognition through the Eighth "China Overseas Chinese Contribution Award."
